ES2439793T3 - Compuestos de pirimidina, su uso como inhibidores de la mTOR quinasa y de la PI3 quinasa, y su síntesis - Google Patents

Compuestos de pirimidina, su uso como inhibidores de la mTOR quinasa y de la PI3 quinasa, y su síntesis Download PDF

Info

Publication number
ES2439793T3
ES2439793T3 ES10716162.2T ES10716162T ES2439793T3 ES 2439793 T3 ES2439793 T3 ES 2439793T3 ES 10716162 T ES10716162 T ES 10716162T ES 2439793 T3 ES2439793 T3 ES 2439793T3
Authority
ES
Spain
Prior art keywords
alkyl
heteroaryl
kinase
inhibitors
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10716162.2T
Other languages
English (en)
Spanish (es)
Other versions
ES2439793T9 (es
Inventor
Jeroen Cunera Verheijen
Arie Zask
David James Richard
Joshua Aaron Kaplan
Kevin Joseph Curran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of ES2439793T3 publication Critical patent/ES2439793T3/es
Publication of ES2439793T9 publication Critical patent/ES2439793T9/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES10716162.2T 2009-04-17 2010-04-15 Compuestos de pirimidina, su uso como inhibidores de la mTOR quinasa y de la PI3 quinasa, y su síntesis Active ES2439793T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17013809P 2009-04-17 2009-04-17
US170138P 2009-04-17
PCT/US2010/031191 WO2010120998A1 (en) 2009-04-17 2010-04-15 Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses

Publications (2)

Publication Number Publication Date
ES2439793T3 true ES2439793T3 (es) 2014-01-24
ES2439793T9 ES2439793T9 (es) 2016-03-10

Family

ID=42269326

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10716162.2T Active ES2439793T3 (es) 2009-04-17 2010-04-15 Compuestos de pirimidina, su uso como inhibidores de la mTOR quinasa y de la PI3 quinasa, y su síntesis

Country Status (6)

Country Link
US (1) US8835429B2 (https=)
EP (1) EP2419432B9 (https=)
JP (1) JP5649643B2 (https=)
CA (1) CA2755554C (https=)
ES (1) ES2439793T3 (https=)
WO (1) WO2010120998A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249129B2 (en) 2010-03-04 2016-02-02 Cellzome Limited Morpholino substituted urea derivatives as mTOR inhibitors
EP2683243A4 (en) * 2011-03-09 2014-12-03 Celgene Avilomics Res Inc PI3 KINASE INHIBITORS AND USES THEREOF
JP2014510122A (ja) * 2011-04-04 2014-04-24 セルゾーム リミテッド mTOR阻害剤としてのジヒドロピロロピリミジン誘導体
ES2609606T3 (es) 2011-09-21 2017-04-21 Cellzome Limited Derivados de urea y carbamato de 2-morfolino-1,3,5-triazina como inhibidores de mTOR para el tratamiento de enfermedades inmunológicas o proliferativas
BR112014008241A2 (pt) 2011-10-07 2017-04-18 Cellzome Ltd composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto
CN104302294A (zh) * 2011-11-01 2015-01-21 埃克塞利希斯股份有限公司 用于治疗淋巴组织增生性恶性肿瘤的作为磷脂酰肌醇3-激酶抑制剂的n-(3-{[(3-{[2-氯-5-(甲氧基)苯基]氨基}喹喔啉-2-基)氨基]磺酰基}苯基)-2-甲基丙氨酰胺
CN104230952B (zh) * 2014-08-16 2017-02-01 沈阳药科大学 含有嘧啶骨架的化合物及其制备方法和用途
AU2015366357B2 (en) * 2014-12-17 2018-07-19 Shanghai Haiyan Pharmaceutical Technology Co. Ltd. 2-morpholin-4,6-disubstituted pyrimidine derivative, and preparation method and pharmaceutical use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9009A (en) * 1852-06-08 Bat-trap
JP2006526652A (ja) * 2003-06-03 2006-11-24 ベス・イスラエル・ディーコニス・メディカル・センター 血管狭窄を治療するための方法及び化合物
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
GB0525083D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
MX2009002046A (es) * 2006-08-24 2009-03-06 Astrazeneca Ab Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos.
CA2688776A1 (en) * 2007-05-18 2008-11-27 Merck & Co., Inc. Oxo bridged diazepan orexin receptor antagonists
US8129371B2 (en) * 2007-10-16 2012-03-06 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors

Also Published As

Publication number Publication date
EP2419432B1 (en) 2013-11-20
CA2755554C (en) 2013-09-24
EP2419432A1 (en) 2012-02-22
ES2439793T9 (es) 2016-03-10
CA2755554A1 (en) 2010-10-21
US8835429B2 (en) 2014-09-16
JP2012524103A (ja) 2012-10-11
JP5649643B2 (ja) 2015-01-07
EP2419432B9 (en) 2016-02-17
WO2010120998A1 (en) 2010-10-21
US20120134959A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
ES2439793T3 (es) Compuestos de pirimidina, su uso como inhibidores de la mTOR quinasa y de la PI3 quinasa, y su síntesis
ES2521596T3 (es) Combinación del compuesto GlyT1 con antipsicóticos
CY1121699T1 (el) Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor
ME02325B (me) Benzoeve kiseline (1-fenil-2-piridin-4-il)-etil estri kao inhibitori fosfodiesteraze
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
ECSP088965A (es) Derivados de 2-tioxantina que actúan como inhibidores de la mpo
WO2007125321A3 (en) Purine and deazapurine derivatives as pharmaceutical compounds
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
MX2009001067A (es) Formas cristalinas de analogos de rapamicina.
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
MX394360B (es) Inhibidores de jak2 y alk2 y metodos para su uso.
PE20090060A1 (es) ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR
PE20130306A1 (es) Morfolinopirimidinas y su uso en terapia
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
CO6251260A2 (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
EA201001017A1 (ru) 3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
MX2011009146A (es) Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acido aminonicotinico como inhibidores de dhodh.
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
SG10201806965XA (en) 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
MX2010008637A (es) Derivado de fenilpirrol novedoso.
EA201290520A1 (ru) Производные дифенилпиразолопиридинов, их получение и применение в качестве модуляторов нуклеарного рецептора not